Collaborative Arrangements and Pending Acquisition - Parion Sciences, Inc. (Details) - USD ($)		1 Months Ended
	Jun. 04, 2015	Jun. 30, 2015	Mar. 31, 2017	Dec. 31, 2016
Business Combination, Consideration Transferred [Abstract]
Intangible assets			$ 284,340,000	$ 284,340,000
Parion Sciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Up-front payment	$ 80,000,000	$ 80,000,000
Prior to marketing approval, time period of notice required to terminate (in days)		90 days
Subsequent to marketing approval, time period of notice required to terminate (in days)		180 days
Change of control prior to clinical trial, time period of notice required to terminate (in days)		30 days
Term of agreement following first commercial sale (in years)		10 years
Business Combination, Consideration Transferred [Abstract]
Intangible assets		$ 255,300,000
Noncontrolling interest, fair value	164,300,000
Deferred tax liabilities, net	91,000,000
Other Liabilities Assets Net	$ 10,500,000
ENaC Inhibitors in CF | Parion Sciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum		490,000,000
Collaborative arrangement regulatory potential milestone payments maximum, global filling and approval		360,000,000
Enac Inhibitors in Non Cf | Parion Sciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum		370,000,000
Additional Enac Inhibitors | Parion Sciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum		$ 230,000,000